Download Posters – Infectious diseases and Vaccines NAME OF THE

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

African trypanosomiasis wikipedia , lookup

Leptospirosis wikipedia , lookup

Eradication of infectious diseases wikipedia , lookup

Yellow fever wikipedia , lookup

Neglected tropical diseases wikipedia , lookup

Norovirus wikipedia , lookup

HIV wikipedia , lookup

Hepatitis C wikipedia , lookup

Influenza A virus wikipedia , lookup

Human cytomegalovirus wikipedia , lookup

Chickenpox wikipedia , lookup

2015–16 Zika virus epidemic wikipedia , lookup

Middle East respiratory syndrome wikipedia , lookup

Ebola virus disease wikipedia , lookup

Orthohantavirus wikipedia , lookup

Zika virus wikipedia , lookup

West Nile fever wikipedia , lookup

Pandemic wikipedia , lookup

Hepatitis B wikipedia , lookup

Herpes simplex virus wikipedia , lookup

Marburg virus disease wikipedia , lookup

Henipavirus wikipedia , lookup

Transcript
Posters –
Infectious diseases and Vaccines
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Dengue & Flaviviruses
Rémi PICARD
SATT Sud Est
A new chemical family to treat tropical diseases induced by Dengue virus and other
Flaviviruses: the hit compounds are non-nucleoside inhibitors active in vitro on a
druggable target (RNA-dependent RNA polymerase (RdRP) NS5), protein of dengue
flavivirus. The viral load will decrease by a short-term treatment.
Technology
This drug family is active against the 4 serotypes of DENV: knowing that immunization
against one of the serotypes does not immunize against the 3 other ones and that all four
serotypes (DENV-1 to 4) can cause the full spectrum of disease, this drug family addresses
a major and actual concern.
Screening platform: more than 17,000 compounds evaluated
Better EC50 among the drug family = 12nM on DENV2
Applications:
Antiviral therapy for Dengue Virus (in severe and lethal dengue hemorrhagic fevers),
West Nile Virus,Yellow Fever Virus, Kunjin Virus and Japanese Encephalitis Virus.
Customers / Target market
Dengue is the most rapidly spreading mosquito-borne viral disease in the world. In the
last 50 years, incidence has increased 30-fold. Over 2.5 billion people – over 40% of the
world's population – are now at risk from dengue. There are around 30,000 deaths per
year.
To date, no antiviral treatment is available.
Industry and competitors
Chemical antiviral compounds could be used in human as: 1st line therapy for infected
individuals, 1st line therapy for travelers (prophylactic), and 2nd line therapy in nonresponders to vaccination
Financing need / Commercial
opportunity
We are currently looking for an industrial partner interested for licensing-in the
technology and/or R&D collaboration (possible co-funding)
IP – Patent situation
Patent: PCT application (June 2014)
Future steps / Milestones
N/A
Further reading
N/A
Contact person
Elodie
Dormes,
Business
[email protected]
Development
Manager,
SATT
Sud
Est,